These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16945074)

  • 1. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.
    Boucher S; Recordon-Pinson P; Ragnaud JM; Dupon M; Fleury H; Masquelier B
    HIV Med; 2006 Jul; 7(5):294-8. PubMed ID: 16945074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. K65R, TAMs and tenofovir.
    Miller MD
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
    Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A
    J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
    Liu L; Lu HZ; Henry M; Tamalet C
    J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
    Wirden M; Marcelin AG; Simon A; Kirstetter M; Tubiana R; Valantin MA; Paris L; Bonmarchand M; Conan F; Kalkias L; Katlama C; Calvez V
    J Med Virol; 2005 Jul; 76(3):297-301. PubMed ID: 15902696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM; Zelina S; Sluis-Cremer N; Mellors JW
    AIDS; 2007 Jul; 21(11):1405-14. PubMed ID: 17589186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
    Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
    J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
    Descamps D; Damond F; Matheron S; Collin G; Campa P; Delarue S; Pueyo S; Chêne G; Brun-Vézinet F;
    J Med Virol; 2004 Oct; 74(2):197-201. PubMed ID: 15332266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    Colson P; Henry M; Tivoli N; Gallais H; Gastaut JA; Moreau J; Tamalet C
    J Med Virol; 2005 Mar; 75(3):381-90. PubMed ID: 15648062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
    Masquelier B; Tamalet C; Montès B; Descamps D; Peytavin G; Bocket L; Wirden M; Izopet J; Schneider V; Ferré V; Ruffault A; Palmer P; Trylesinski A; Miller M; Brun-Vézinet F; Costagliola D;
    Antivir Ther; 2004 Jun; 9(3):315-23. PubMed ID: 15259894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
    Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
    Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.